Cancer Breakthrough: A New Era for Personalized Medicine? The latest news from Merck and Moderna's joint effort has sent shockwaves through the medical community and stock markets.
An experimental personalized cancer vaccine, in combination with immunotherapy Keytruda, has shown promising results in a late stage trial involving over 1,100 patients with advanced melanoma.
This breakthrough challenges the traditional one size fits all approach to cancer therapy.